Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. As of December 31, 2010, the Company had one marketed product: ARCALYST (rilonacept) injection for subcutaneous use, which is available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Its late stage programs are VEGF Trap-Eye (aflibercept ophthalmic solution), which is being developed for the prevention and treatment of serious eye diseases; ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment, and aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group.
Faizan's take
REGN closed at $65.2 a share on Friday. This stock has a lot of momentum on its side, and can make a decent up move in the next couple of months.
Price target $74 (12.8% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
Today REGN bounced off its most recent break out support. Looking for a sustained rally from here on.
ReplyDeleteTarget price was reached on heavy trading volume on 21st September 2011
ReplyDeleteRegeneron has two products in development based on aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.
ReplyDelete